Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | IL2 | P60568 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886094 | 0.90 | KDM4E (0.53) | KDM4EHTTLMNAMAPTIL2 | |
| SCHEMBL18987369 | 0.89 | KDM4E (0.51) | KDM4EHTTLMNAMAPTIL2 | |
| SCHEMBL20971905 | 0.86 | KDM4E (0.49) | KDM4EHTTLMNAMAPTIL2 | |
| SCHEMBL7223413 | 0.84 | KDM4E (0.47) | KDM4EHTTLMNAMAPTIL2 | |
| SCHEMBL9754434 | 0.83 | IL2 (0.46) | KDM4EHTTLMNAMAPTIL2 | |
| SCHEMBL7219394 | 0.83 | KDM4E (0.46) | KDM4EHTTLMNAMAPTIL2 | |
| SCHEMBL610883 | 0.82 | HTT (0.47) | KDM4EHTTLMNAMAPTIL2 | |
| SCHEMBL7223905 | 0.81 | KDM4E (0.53) | KDM4EHTTLMNAMAPTIL2 | |
| SCHEMBL31048531 | 0.81 | KDM4E (0.53) | KDM4EHTTLMNAMAPTIL2 | |
| SCHEMBL9330597 | 0.81 | KDM4E (0.43) | KDM4EHTTLMNAMAPTIL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807609-B2 | Deuterated compounds as immunomodulators | CHEMOCENTRYX, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807609-B2 | Deuterated compounds as immunomodulators | CHEMOCENTRYX, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807609-B2 | Deuterated compounds as immunomodulators | CHEMOCENTRYX, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20210276955-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | CHEMOCENTRYX, INC. | 2021-09-09 | — | — | US | disclosed |
| US-20210276955-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | CHEMOCENTRYX, INC. | 2021-09-09 | — | — | US | disclosed |
| CN-111741754-A | Deuterated compounds as immunomodulators | 凯莫森特里克斯股份有限公司 | 2020-10-02 | — | — | CN | disclosed |
| EP-3703687-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | ChemoCentryx, Inc. (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20190144389-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | CHEMOCENTRYX, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190144389-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | CHEMOCENTRYX, INC. | 2019-05-16 | — | — | US | disclosed |
| US-8283373-B2 | Inhibitors of cytosolic phospholipase A2 | PFIZER INC. (US) | 2012-10-09 | — | — | US | disclosed |
| WO-1997034893-A1 | PHARMACEUTICALLY USEFUL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1997-09-25 | — | — | WO | disclosed |
| US-5498630-A | SUBSTITUTED BENZOTHIOPHENECARBOXAMIDES | MONSANTO COMPANY (US) | 1996-03-12 | — | — | US | disclosed |
| US-5283361-A | Treating asthma, arthritis, allergy, psoriasis, shock, adult respiratory distress syndrome, ischemia, inflammatory bowel disease | ELI LILLY AND COMPANY (US) | 1994-02-01 | — | — | US | disclosed |
| WO-1993007751-A1 | FUNGICIDES FOR THE CONTROL OF TAKE-ALL DISEASE OF PLANTS | MONSANTO COMPANY (US) | 1993-04-29 | — | — | WO | disclosed |
| EP-0538231-A1 | Fungicides for the control of take-all disease of plants | MONSANTO COMPANY (US) | 1993-04-21 | — | — | EP | disclosed |
| EP-0510948-A1 | N-Hydroxy ureae as 5-lipoxygenase inhibitors | ELI LILLY AND COMPANY (US) | 1992-10-28 | — | — | EP | disclosed |
| WO-1991013065-A1 | 6-ARYL-2-SUBSTITUTED BENZOIC ACID HERBICIDES | FMC CORPORATION (US) | 1991-09-05 | — | — | WO | disclosed |
| EP-0210140-B1 | INHIBITORS OF BENZYLAMINOXIDASES, SELECTIVE WITH RESPECT TO OTHER AMINOXIDASES | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1990-06-13 | — | — | EP | disclosed |
| US-4888283-A | Selective inhibitors of benzylaminoxidases with respect to other aminoxidases | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1989-12-19 | — | — | US | disclosed |
| EP-0210140-A2 | Inhibitors of benzylaminoxidases, selective with respect to other aminoxidases | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1987-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807609-B2 | Deuterated compounds as immunomodulators | C3AR1, C5AR1, C5AR2 | KDM4E 3617/4885HTT 4047/4885LMNA 4857/4885 |
| US-20190144389-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | C3AR1, C5AR1, C5AR2 | KDM4E 3617/4885HTT 4047/4885LMNA 4857/4885 |
| US-20210276955-A1 | DEUTERATED COMPOUNDS AS IMMUNOMODULATORS | C3AR1, C5AR1, C5AR2 | KDM4E 3617/4885HTT 4047/4885LMNA 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.